- Home
- TXO vs KURA Comparison
TXO vs KURA Comparison
Compare TXO & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXO
- KURA
- Stock Information
- Founded
- TXO 2012
- KURA 2014
- Country
- TXO United States
- KURA United States
- Employees
- TXO N/A
- KURA N/A
- Industry
- TXO Oil & Gas Production
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TXO Energy
- KURA Health Care
- Exchange
- TXO Nasdaq
- KURA Nasdaq
- Market Cap
- TXO 692.7M
- KURA 793.2M
- IPO Year
- TXO 2023
- KURA N/A
- Fundamental
- Price
- TXO $19.35
- KURA $7.39
- Analyst Decision
- TXO Strong Buy
- KURA Strong Buy
- Analyst Count
- TXO 2
- KURA 11
- Target Price
- TXO $26.00
- KURA $27.89
- AVG Volume (30 Days)
- TXO 116.0K
- KURA 1.5M
- Earning Date
- TXO 03-04-2025
- KURA 02-25-2025
- Dividend Yield
- TXO 12.29%
- KURA N/A
- EPS Growth
- TXO N/A
- KURA N/A
- EPS
- TXO N/A
- KURA N/A
- Revenue
- TXO $285,451,000.00
- KURA N/A
- Revenue This Year
- TXO N/A
- KURA N/A
- Revenue Next Year
- TXO $28.33
- KURA $233.30
- P/E Ratio
- TXO N/A
- KURA N/A
- Revenue Growth
- TXO N/A
- KURA N/A
- 52 Week Low
- TXO $15.22
- KURA $6.98
- 52 Week High
- TXO $23.56
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- TXO 75.83
- KURA 22.90
- Support Level
- TXO $16.49
- KURA $7.02
- Resistance Level
- TXO $19.50
- KURA $7.66
- Average True Range (ATR)
- TXO 0.67
- KURA 0.33
- MACD
- TXO 0.32
- KURA 0.10
- Stochastic Oscillator
- TXO 95.02
- KURA 21.58
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization and exploitation of oil, natural gas, and natural gas liquid reserves in North America.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.